Company Continues to Build and Expand the Global IP Portfolio of
Its One-of-a-Kind Technology
Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven
precision cardiovascular medicine company, announces that the U.S.
Patent and Trademark Office has issued a notice of allowance to
University of Iowa Research Foundation ("UIRF") for U.S.
Application No. 17,857,723 titled Compositions and Methods for
Detecting Predisposition to Cardiovascular Disease, which is
exclusively licensed to the Company from UIRF, and that was
co-invented by Cardio Diagnostics' founders, Meesha Dogan, Ph.D.,
and Robert Philibert, MD Ph.D., the Chief Executive Officer and
Chief Medical Officer of the Company, respectively. This is the
second U.S. patent being issued in this patent family. Patents in
this patent family have also been issued in the European Union,
China, India, and Australia.
Among Escalating CVD Burden, Company Continues to Expand IP
Portfolio
According to the American Heart Association, cardiovascular
disease (CVD) claims 2,552 lives daily in the United States,
translating to a death every 34 seconds. Heart disease, which
includes heart attacks, has been the leading cause of death in the
United States for 100 years. On average, a heart attack occurs
every 40 seconds in the U.S., with around 605,000 new and 200,000
recurrent heart attacks reported annually.
Unfortunately, an estimated 170,000 of these heart attacks are
silent, occurring without significant symptoms. This can mean that
many Americans with a silent event are not being identified as at
high risk early enough, nor are they being identified after the
event. These figures underscore the critical health burden posed by
CVD and heart disease in the U.S., highlighting the urgent need for
enhanced prevention, detection, management, and treatment
strategies. The Company continues to expand the IP portfolio
protections associated with its Integrated Epigenetic-Genetic
Engine technology, which lies at the heart of its solutions to this
growing burden. The Company's IP portfolio also encompasses its
clinical blood tests, Epi+Gen CHDTM and PrecisionCHDTM, and
software solutions, HeartRiskTM and CardioInnovate360TM.
Meesha Dogan, Ph.D., CEO and Co-Founder of Cardio Diagnostics,
stated, "The issuance of our latest patent helps us further protect
our precision technology and solutions that harness the power of
advanced genomics, advanced epigenomics, and artificial
intelligence for the risk assessment, diagnosis, treatment,
management and monitoring of cardiovascular disease. Our Precision
Medicine solutions enable healthcare stakeholders, from patients,
clinicians, and payors to employers, to make data-driven clinical,
personal, and business decisions to get ahead of the human toll and
financial burden of heart disease."
Solutions Built on Current IP Portfolio
Epi+Gen CHD: An integrated genetic-epigenetic
blood test to assess the three-year risk for coronary heart disease
(CHD) events, particularly heart attacks or sudden death associated
with CHD.
PrecisionCHD: An integrated genetic-epigenetic
blood test to aid in diagnosing coronary heart disease.
HeartRisk: A cardiovascular disease risk
intelligence platform to enable data-driven multi-stakeholder
collaborations among patients, innovative providers, health plans,
employers, and governmental entities to drive transformative risk
stratification in heart disease and enhance earlier prevention and
interventions.
CardioInnovate360: A biopharma research solution that
offers three pivotal capabilities: the identification of novel
biomarkers and pathways critical in CVD pathogenesis, patient
stratification for enhanced clinical trial efficacy, and the
development of non-invasive, scalable post-market surveillance and
companion diagnostic tests.
The Company's AI-driven integrated epigenetic-genetic
technologies for cardiovascular disease are scalable, accessible,
and highly sensitive. The Company's IP strategy is designed to
enhance the global protections of its one-of-a-kind technology.
About Cardio Diagnostics
Cardio Diagnostics is an artificial intelligence-powered
precision cardiovascular medicine company that makes cardiovascular
disease prevention, detection, and management more accessible,
personalized, and precise. The Company was formed to further
develop and commercialize clinical tests by leveraging a
proprietary Artificial Intelligence (AI)-driven Integrated
Genetic-Epigenetic Engine ("Core Technology") for cardiovascular
disease to become one of the leading medical technology companies
for improving prevention, detection, and treatment of
cardiovascular disease. For more information, please visit
www.cardiodiagnosticsinc.com.
Forward-Looking Statements
Certain statements and information included in this press
release constitute "forward-looking statements" within the meaning
of the Private Securities Litigation Act of 1995. When used in this
press release, the words or phrases "will," "will likely result,"
"expected to," "will continue," "anticipated," "estimate,"
"projected," "intend," "goal," or similar expressions are intended
to identify "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements
are subject to certain risks, known and unknown, and uncertainties,
many of which are beyond the control of the Company. Such
uncertainties and risks include but are not limited to, our ability
to successfully execute our growth strategy, changes in laws or
regulations, economic conditions, dependence on management,
dilution to stockholders, lack of capital, the effects of rapid
growth upon the Company and the ability of management to
effectively respond to the growth and demand for products and
services of the Company, newly developing technologies, the
Company's ability to compete, regulatory matters, protection of
technology, the effects of competition and the ability of the
Company to obtain future financing. An extensive list of factors
that can affect future results are discussed in the Current Report
on Form 10-K for the period ended December 31, 2022, and Forms 10-Q
for the period ended March 31, 2023, and September 30, 2023, under
the heading "Risk Factors" in Part I, Item IA thereof, and other
documents filed from time to time with the Securities and Exchange
Commission. Such factors could materially adversely affect the
Company's financial performance and could cause the Company's
actual results for future periods to differ materially from any
opinions or statements expressed within this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240305535830/en/
Investors: Gene Mannheimer Investor Relations 855-226-9991
investors@cardiodiagnosticsinc.com
Media & Public Relations: Khullani Abdullahi 855-226-9991
pr@cardiodiagnosticsinc.com
Cardio Diagnostics (NASDAQ:CDIO)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
Cardio Diagnostics (NASDAQ:CDIO)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025
